[go: up one dir, main page]

HUE048780T2 - Tauopátia kezelésére szolgáló módszerek - Google Patents

Tauopátia kezelésére szolgáló módszerek

Info

Publication number
HUE048780T2
HUE048780T2 HUE13830020A HUE13830020A HUE048780T2 HU E048780 T2 HUE048780 T2 HU E048780T2 HU E13830020 A HUE13830020 A HU E13830020A HU E13830020 A HUE13830020 A HU E13830020A HU E048780 T2 HUE048780 T2 HU E048780T2
Authority
HU
Hungary
Prior art keywords
methods
treating tauopathy
tauopathy
treating
Prior art date
Application number
HUE13830020A
Other languages
English (en)
Inventor
Irene Griswold-Prenner
Nancy E Stagliano
Vu Dang
Original Assignee
Ipierian Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipierian Inc filed Critical Ipierian Inc
Publication of HUE048780T2 publication Critical patent/HUE048780T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
HUE13830020A 2012-08-16 2013-08-15 Tauopátia kezelésére szolgáló módszerek HUE048780T2 (hu)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261683902P 2012-08-16 2012-08-16
US201361754085P 2013-01-18 2013-01-18
US201361781823P 2013-03-14 2013-03-14
US201361813797P 2013-04-19 2013-04-19
US201361833355P 2013-06-10 2013-06-10

Publications (1)

Publication Number Publication Date
HUE048780T2 true HUE048780T2 (hu) 2020-09-28

Family

ID=50101612

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13830020A HUE048780T2 (hu) 2012-08-16 2013-08-15 Tauopátia kezelésére szolgáló módszerek

Country Status (33)

Country Link
US (6) US9567395B2 (hu)
EP (2) EP3685854A1 (hu)
JP (1) JP6290212B2 (hu)
KR (1) KR102076384B1 (hu)
CN (1) CN104736185B (hu)
AU (1) AU2013302540B2 (hu)
BR (1) BR112015003326A2 (hu)
CA (1) CA2882034C (hu)
CL (1) CL2015000352A1 (hu)
CY (1) CY1123515T1 (hu)
DK (1) DK2885010T3 (hu)
EA (2) EA035976B1 (hu)
ES (1) ES2775192T3 (hu)
GB (1) GB2507207A (hu)
HK (1) HK1208175A1 (hu)
HR (1) HRP20200036T1 (hu)
HU (1) HUE048780T2 (hu)
IL (1) IL237153B (hu)
LT (1) LT2885010T (hu)
ME (1) ME03667B (hu)
MX (1) MX359817B (hu)
MY (1) MY176838A (hu)
NZ (2) NZ630542A (hu)
PE (1) PE20150646A1 (hu)
PH (1) PH12015500196B1 (hu)
PL (1) PL2885010T3 (hu)
PT (1) PT2885010T (hu)
RS (1) RS60080B1 (hu)
SG (2) SG11201500888SA (hu)
SI (1) SI2885010T1 (hu)
SM (1) SMT202000180T1 (hu)
TN (1) TN2015000050A1 (hu)
WO (1) WO2014028777A2 (hu)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
RU2668159C2 (ru) 2012-07-03 2018-09-26 Вашингтон Юниверсити Антитела против тау
WO2014028777A2 (en) 2012-08-16 2014-02-20 Ipierian, Inc. Methods of treating a tauopathy
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
EP2970453B1 (en) 2013-03-13 2019-12-04 Prothena Biosciences Limited Tau immunotherapy
BR112015030356A2 (pt) * 2013-06-10 2017-12-05 Ipierian Inc métodos de tratamento de uma taupatia
JP6629201B2 (ja) * 2013-11-27 2020-01-15 アイピエリアン，インコーポレイティド タウオパチーの処置方法
ES2778498T3 (es) 2013-12-20 2020-08-10 Hoffmann La Roche Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TWI734975B (zh) * 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
AR103713A1 (es) 2015-02-26 2017-05-31 Lilly Co Eli Anticuerpos contra tau y sus usos
WO2016146655A1 (en) 2015-03-16 2016-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel 1,4-bis(3-aminopropyl)piperazine derivative and its use
SG10201911349YA (en) * 2015-06-05 2020-01-30 Genentech Inc Anti-tau antibodies and methods of use
EP3307320A4 (en) * 2015-06-12 2019-03-06 C2N Diagnostics LLC Stable formulations of humanized anti-tau antibodies
ES2826827T3 (es) 2015-06-15 2021-05-19 Angiochem Inc Métodos para el tratamiento de carcinomatosis leptomeníngea
ES2809728T3 (es) 2015-06-24 2021-03-05 Hoffmann La Roche Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
JP6937289B2 (ja) 2015-07-06 2021-09-22 ユーシービー バイオファルマ エスアールエル Ｔａｕ結合抗体
MA41670A1 (fr) * 2015-07-06 2018-05-31 Ucb Biopharma Sprl Anticorps se liant a tau
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
PT3334761T (pt) * 2015-08-13 2023-08-17 Univ New York Moléculas baseadas em anticorpo seletivo para o epítopo {p}ser404 da tau e os seus usos no diagnóstico e tratamento de tauopatias
KR102506091B1 (ko) 2016-05-02 2023-03-07 프로테나 바이오사이언시즈 리미티드 타우 면역요법
EP3452508A1 (en) 2016-05-02 2019-03-13 Prothena Biosciences Limited Antibodies recognizing tau
US10906964B2 (en) 2016-05-02 2021-02-02 Prothena Biosciences Limited Antibodies recognizing tau
AU2017295608B2 (en) 2016-07-12 2024-01-04 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau and methods of use thereof
CA3030754C (en) * 2016-07-20 2022-04-26 Anahit Ghochikyan Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
CN109562067A (zh) * 2016-08-02 2019-04-02 库里尔克思股份有限公司 制备脂质体的方法
US10988529B2 (en) 2016-08-09 2021-04-27 Eli Lilly And Company Combination therapy
KR20240035636A (ko) 2016-12-07 2024-03-15 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
KR20230146126A (ko) 2016-12-07 2023-10-18 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
MX2019009817A (es) 2017-02-17 2019-11-21 Denali Therapeutics Inc Anticuerpos anti-tau y metodos de uso de los mismos.
JP2018139530A (ja) * 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
TWI848907B (zh) 2017-03-28 2024-07-21 美商建南德克公司 治療神經退化性疾病之方法
US11958896B2 (en) 2017-05-02 2024-04-16 Prothena Biosciences Limited Antibodies recognizing tau
AU2017418317A1 (en) * 2017-06-16 2019-12-05 Bristol-Myers Squibb Company Compositions and methods for treating tauopathies
PE20210115A1 (es) 2017-10-16 2021-01-19 Eisai Randd Man Co Ltd Anticuerpos anti-tau y uso de los mismos
CN108103027B (zh) * 2018-02-02 2021-12-24 中国医学科学院血液病医院（血液学研究所） 高效率血细胞重编程同时实现基因编辑的方法
BR112021000895A2 (pt) * 2018-07-19 2021-04-13 Genentech, Inc. Métodos para identificar um indivíduo como possuindo ou estando em risco de desenvolver uma demência positiva para amilóide e para detectar um indivíduo com um valor aumentado para uma combinação de marcadores e uso de ass40, ass42 e ttau
EP3829634A1 (en) 2018-07-31 2021-06-09 Eli Lilly and Company Combination therapy
EA202191179A1 (ru) 2018-10-29 2021-09-09 Байоджен Ма Инк. Гуманизированные и стабилизированные варианты fc5 для улучшения транспорта через гематоэнцефалический барьер
WO2020096608A1 (en) * 2018-11-08 2020-05-14 Prothena Biosciences Limited Antibodies recognizing tau
WO2020153940A1 (en) * 2019-01-22 2020-07-30 Clemson University Anti-elastin antibodies and methods of use
SG11202108414UA (en) 2019-03-03 2021-08-30 Prothena Biosciences Ltd Antibodies recognizing tau
JP7181438B2 (ja) 2019-08-06 2022-11-30 アプリノイア セラピューティクス リミテッド 病理学的タウ種に結合する抗体及びその使用
EP4069273A1 (en) * 2019-12-05 2022-10-12 Axoltis Pharma Peptide compositions and methods for treating tauopathies
EP4135841A1 (en) 2020-04-15 2023-02-22 Voyager Therapeutics, Inc. Tau binding compounds
EP4171633A1 (en) 2020-06-25 2023-05-03 Merck Sharp & Dohme LLC High affinity antibodies targeting tau phosphorylated at serine 413
JP2023554382A (ja) 2020-12-16 2023-12-27 ボイジャー セラピューティクス インコーポレイテッド タウ結合化合物
IL310382A (en) 2021-08-27 2024-03-01 Genentech Inc Methods for treating tau pathologies
CA3231228A1 (en) * 2021-09-09 2023-03-16 Andreas Jeromin Phospho-tau antibodies and methods of use
JP2024540294A (ja) * 2021-11-03 2024-10-31 バイオジェン・エムエイ・インコーポレイテッド アルツハイマー病を治療するための方法
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN118871989A (zh) 2022-03-14 2024-10-29 基因泰克公司 基于语音分析来预测神经退行性疾病
CN119404251A (zh) 2022-06-21 2025-02-07 基因泰克公司 基于言语分析检测阿尔茨海默病(ad)的纵向进展
WO2023250388A1 (en) 2022-06-22 2023-12-28 Voyager Therapeutics, Inc. Tau binding compounds
WO2024059739A1 (en) 2022-09-15 2024-03-21 Voyager Therapeutics, Inc. Tau binding compounds
CN116948025B (zh) * 2023-09-14 2024-04-02 北京凯祥弘康生物科技有限公司 一种抗Tau蛋白的抗体

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4866132A (en) 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5256334A (en) 1988-09-08 1993-10-26 The Research Foundation Of The State University Of New York Homogeneous radiopaque polymer-organobismuth composites
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP0600951A4 (en) 1991-08-01 1996-10-30 Paul H Voorheis Diagnostic method for alzheimer's disease.
US5733734A (en) 1991-08-14 1998-03-31 The Trustees Of The University Of Pennsylvania Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
EP0648271B1 (en) 1991-08-20 2003-04-16 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Adenovirus mediated transfer of genes to the gastrointestinal tract
CA2119930C (en) 1991-09-23 2002-10-01 Hendricus R. J. M. Hoogenboom Production of chimeric antibodies - a combinatorial approach
WO1993008302A1 (en) * 1991-10-25 1993-04-29 Itt Automotive Europe Gmbh Monoclonal antibodies directed against the microtubule-associated protein tau
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JP2579202Y2 (ja) 1992-04-10 1998-08-20 株式会社小松製作所 圧力補償弁を備えた操作弁
US5600392A (en) 1992-11-25 1997-02-04 Copal Company Limited Position sensor
EP0905253A3 (en) 1992-12-03 2000-11-02 Genzyme Corporation Adenoviral vector deleted of all E4-ORF except ORF6
US5843779A (en) 1992-12-14 1998-12-01 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, and hybridomas secreting these antibodies
US6010913A (en) 1992-12-14 2000-01-04 N.V. Innogenetics S.A. Isolated human tau peptide
US5346981A (en) 1993-01-13 1994-09-13 Miles Inc. Radiopaque polyurethanes
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
ATE304604T1 (de) 1993-06-24 2005-09-15 Frank L Graham Adenovirus vektoren für gentherapie
BR9407956A (pt) 1993-10-25 1996-11-26 Canji Inc Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
ATE335007T1 (de) 1993-12-21 2006-08-15 Innogenetics Nv Monoklonale antikörper gegen phf-tau, hybridomen die diese ausscheiden, antigenerkennung durch diesen antikörper und deren verwendungen
WO1996004309A1 (en) 1994-07-29 1996-02-15 Innogenetics N.V. Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications
US5625048A (en) 1994-11-10 1997-04-29 The Regents Of The University Of California Modified green fluorescent proteins
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
AU711524C (en) 1994-12-09 2004-03-18 Emergent Product Development Uk Limited Identification of genes
AU4188196A (en) 1994-12-22 1996-07-10 Nissan Chemical Industries Ltd. Organobismuth derivatives and process for producing the same
US5958713A (en) 1995-01-31 1999-09-28 Novo Nordisk A/S Method of detecting biologically active substances by using green fluorescent protein
US5670477A (en) 1995-04-20 1997-09-23 Joseph F. Poduslo Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents
US5968738A (en) 1995-12-06 1999-10-19 The Board Of Trustees Of The Leland Stanford Junior University Two-reporter FACS analysis of mammalian cells using green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US6020192A (en) 1996-01-18 2000-02-01 University Of Florida Humanized green fluorescent protein genes and methods
CA2264735C (en) 1996-08-27 2008-01-29 Chiron Corporation Neisseria meningitidis serogroup b glycoconjugates and methods of using the same
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
TW371617B (en) 1996-10-09 1999-10-11 Of Animal And Plant Health Inspection And Quarantine Council Of Agriculture Executive Yuan Bureau Method to transplant GFP into autographa californica multiple nuclear polyhedrosis virus for inflicting pest in an attempt to detect and flow up it existence and to improve life span against UV
WO1998022120A1 (en) 1996-11-19 1998-05-28 The Wistar Institute Of Anatomy & Biology Diagnostic and therapeutic reagents for alzheimer's disease
US6080849A (en) 1997-09-10 2000-06-27 Vion Pharmaceuticals, Inc. Genetically modified tumor-targeted bacteria with reduced virulence
CA2313225A1 (en) 1997-12-12 1999-06-17 Macromed, Inc. Heterofunctionalized star-shaped poly(ethylene glycols) for protein modification
US20040014142A1 (en) 1998-07-03 2004-01-22 Innogenetics N.V. Differential diagnosis of neurodegeneration
US5985577A (en) 1998-10-14 1999-11-16 The Trustees Of Columbia University In The City Of New York Protein conjugates containing multimers of green fluorescent protein
AU6234700A (en) 1999-07-27 2001-02-13 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
WO2001055725A2 (en) 2000-01-24 2001-08-02 Innogenetics N.V. Diagnosis of tauopathies determining tau/phospho-tau ratio
DE60141752D1 (de) 2000-06-30 2010-05-20 Innogenetics Nv Differentielle diagnose von neurologischen krankheiten
AU2001273361A1 (en) 2000-07-11 2002-01-21 Molecular Geriatrics Corporation Reagents and methods for identification of binding agents
AU2002222139A1 (en) * 2000-12-09 2002-06-18 Cambridge University Technical Services Limited Hcv vaccines
US7466180B2 (en) 2000-12-12 2008-12-16 Intel Corporation Clock network
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
GB0105924D0 (en) 2001-03-09 2001-04-25 Microscience Ltd Promoter
US6821504B2 (en) 2001-05-23 2004-11-23 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
GB0117326D0 (en) 2001-07-16 2001-09-05 Univ Aberdeen Napthoquinone-type inhibitors of protein aggregation
JP2004538324A (ja) 2001-08-03 2004-12-24 メディカル リサーチ カウンシル 細胞内抗体
AR043700A1 (es) 2001-09-21 2005-08-10 Mitsubishi Pharma Corp Derivados de 3-substituida-4-pirimidona
WO2004001421A2 (en) 2002-06-21 2003-12-31 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
DE60323231D1 (de) 2002-07-12 2008-10-09 Axon Neuroscience Verkürzte tau proteine
US7250551B2 (en) 2002-07-24 2007-07-31 President And Fellows Of Harvard College Transgenic mice expressing inducible human p25
JP4393382B2 (ja) 2002-08-14 2010-01-06 三菱化学株式会社 中枢性タウ蛋白質特異的抗体
EP1480041A1 (en) 2003-05-22 2004-11-24 Innogenetics N.V. Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
PT1641822E (pt) 2003-07-08 2013-08-27 Genentech Inc Polipéptidos heterólogos il-17 a/f e suas utilizações terapêuticas
US20050261475A1 (en) 2004-02-13 2005-11-24 Harvard Medical School Solid-phase capture-release-tag methods for phosphoproteomic analyses
WO2005080986A1 (en) * 2004-02-18 2005-09-01 University Of Iowa Research Foundation Antibodies to phosphorylated tau, methods of making and methods of use
US20050191685A1 (en) 2004-02-24 2005-09-01 Innogenetics N.V. Method for determining the risk of developing a neurological disease
US7456027B2 (en) 2004-04-15 2008-11-25 University Of Florida Research Foundation, Inc. Proteolytic biomarkers for traumatic injury to the nervous system
WO2005120166A2 (en) 2004-06-09 2005-12-22 Technion Research & Development Foundation Ltd. Antibodies for selective apoptosis of cells
WO2006009901A2 (en) 2004-06-18 2006-01-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
CN1721437A (zh) * 2004-07-13 2006-01-18 中南大学 一种与Tau蛋白相关的多肽抗原及抗体
JP4730584B2 (ja) 2004-12-06 2011-07-20 東亞合成株式会社 抗菌ペプチド及びその利用
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
EP1772732A1 (en) 2005-10-07 2007-04-11 Innogenetics N.V. Polymer replicated interdigitated electrode arrays for (bio)sensing applications
US8741260B2 (en) 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
WO2007068105A1 (en) 2005-12-12 2007-06-21 Robarts Research Institute Method of diagnosing amyotrophic lateral sclerosis
US20070218491A1 (en) 2006-02-08 2007-09-20 Oligomerix, Inc. Oligomerization of amyloid proteins
US20110143380A1 (en) 2006-03-14 2011-06-16 The Washington University Alzheimer's disease biomarkers and methods of use
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US8729225B2 (en) 2006-11-13 2014-05-20 Intrexon Corporation Glycogen synthase kinase heteropolyligand polypeptide
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
US20080220449A1 (en) 2007-02-08 2008-09-11 Oligomerix, Inc. Biomarkers and assays for Alzheimer's disease
US8178317B2 (en) 2007-05-01 2012-05-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for identifying transforming and tumor suppressor genes
US20090175847A1 (en) 2007-05-30 2009-07-09 Abbott Laboratories Humanized antibodies to ab (20-42) globulomer and uses thereof
US8481277B2 (en) 2007-08-21 2013-07-09 Washington University Alzheimer's diagnosis
JP2010536907A (ja) 2007-08-31 2010-12-02 ニューリミューン セラピューティクス エイジー 患者にアミロイドーシスおよびタンパク質凝集性障害における特異的免疫応答をもたらす方法
WO2009033151A1 (en) 2007-09-07 2009-03-12 The Trustees Of Columbia University In The City Of New York Tau protein screening assay
US8506933B2 (en) 2007-11-30 2013-08-13 Msdx, Inc. Methods of detecting a neurological condition via analysis of circulating phagocytes
WO2010009277A2 (en) 2008-07-15 2010-01-21 Novartis Ag Immunogenic amphipathic peptide compositions
US9464122B2 (en) 2008-08-20 2016-10-11 Oligomerix, Inc. Methods and compositions comprising tau oligomers
WO2010021755A2 (en) 2008-08-20 2010-02-25 Oligomerix, Inc. Tau protease compositions and methods
CN103665170A (zh) 2008-12-05 2014-03-26 安吉奥开米公司 肽治疗剂轭合物及其应用
US9605054B2 (en) 2009-02-23 2017-03-28 The Board Of Trustees Of The University Of Illinois Composition and method for treating a tauopathy
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
US8409584B2 (en) 2009-05-05 2013-04-02 New York University Immunotherapy targeting of the shared abnormal conformational state of amyloidogenic peptides/proteins
CN103154735B (zh) 2009-05-11 2018-10-02 连接Dx股份有限公司 用于检测分析物的方法和组合物
CN102596221B (zh) 2009-06-10 2019-06-04 纽约大学 病理tau蛋白的免疫靶向
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CA2768346A1 (en) 2009-07-30 2011-02-03 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
JP6124591B2 (ja) 2009-08-28 2017-05-10 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム タウオリゴマーに結合する抗体
EP2496594B1 (en) 2009-11-06 2018-01-17 The J. David Gladstone Institutes Methods and compositions for modulating tau levels
US9289488B2 (en) 2010-08-12 2016-03-22 Ac Immune Sa Vaccine engineering
MX338421B (es) 2010-10-07 2016-04-15 Ac Immune Sa Anticuerpos fosfoespecificos que reconocen la proteina tau.
PL2627672T3 (pl) 2010-10-11 2018-11-30 Biogen International Neuroscience Gmbh Ludzkie przeciwciała anty-tau
EP2670434B1 (en) 2011-01-31 2018-12-26 Tau Bio-Logic Corp. Treatment of tauopathies
JP6196163B2 (ja) 2011-03-17 2017-09-13 ミネルバ バイオテクノロジーズ コーポレーション 多能性幹細胞を作製する方法
GB201111361D0 (en) 2011-07-04 2011-08-17 Nordic Bioscience As Biochemical markers for neurodegenerative conditions
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
PL2758433T3 (pl) 2011-09-19 2018-06-29 Axon Neuroscience Se Oparta na białku terapia i diagnozowanie patologii zależnej od Tau w chorobie Alzheimera
CA2811188C (en) 2011-09-23 2020-04-28 Andrea Pfeifer Vaccine therapy
ES2600915T3 (es) 2011-10-07 2017-02-13 Ac Immune S.A. Anticuerpos fosfoespecíficos que reconocen Tau
US20140294724A1 (en) 2011-10-24 2014-10-02 Intellect Neurosciences, Inc. Compositions and methods for treatment of proteinopathies
MX350311B (es) 2011-12-20 2017-09-01 Janssen Biotech Inc Anticuerpos anti-phf-tau y sus usos.
BR112014024769A2 (pt) 2012-04-05 2017-12-12 Ac Immune Sa anticorpo humanizado tau
RU2668159C2 (ru) 2012-07-03 2018-09-26 Вашингтон Юниверсити Антитела против тау
WO2014028777A2 (en) 2012-08-16 2014-02-20 Ipierian, Inc. Methods of treating a tauopathy
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
US20160122421A1 (en) 2013-06-10 2016-05-05 Ipierian, Inc. Methods of treating a tauopathy
BR112015030356A2 (pt) * 2013-06-10 2017-12-05 Ipierian Inc métodos de tratamento de uma taupatia
JP6629201B2 (ja) 2013-11-27 2020-01-15 アイピエリアン，インコーポレイティド タウオパチーの処置方法
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法

Also Published As

Publication number Publication date
HRP20200036T1 (hr) 2020-08-21
SMT202000180T1 (it) 2020-05-08
EA201590388A1 (ru) 2015-08-31
WO2014028777A3 (en) 2014-05-08
US20140099304A1 (en) 2014-04-10
EP2885010A2 (en) 2015-06-24
GB201322812D0 (en) 2014-02-05
US20140086921A1 (en) 2014-03-27
PH12015500196A1 (en) 2015-04-06
EP2885010B1 (en) 2020-01-01
CA2882034C (en) 2019-10-29
TN2015000050A1 (en) 2016-06-29
US20170174755A1 (en) 2017-06-22
AU2013302540A1 (en) 2015-04-02
PL2885010T3 (pl) 2020-11-16
MY176838A (en) 2020-08-24
NZ630542A (en) 2017-06-30
KR102076384B1 (ko) 2020-02-11
ES2775192T3 (es) 2020-07-24
EP3685854A1 (en) 2020-07-29
SG10201701181XA (en) 2017-04-27
SI2885010T1 (sl) 2020-07-31
US10040847B2 (en) 2018-08-07
GB2507207A (en) 2014-04-23
MX359817B (es) 2018-10-11
BR112015003326A2 (pt) 2017-07-04
ME03667B (me) 2020-10-20
CN104736185B (zh) 2018-03-20
KR20150042828A (ko) 2015-04-21
US20150239963A1 (en) 2015-08-27
US20190169275A1 (en) 2019-06-06
SG11201500888SA (en) 2015-03-30
HK1208175A1 (zh) 2016-02-26
US8926974B2 (en) 2015-01-06
WO2014028777A2 (en) 2014-02-20
JP6290212B2 (ja) 2018-03-07
PE20150646A1 (es) 2015-05-21
DK2885010T3 (da) 2020-02-03
NZ730763A (en) 2018-06-29
CN104736185A (zh) 2015-06-24
JP2015532592A (ja) 2015-11-12
AU2013302540B2 (en) 2018-02-15
EA035976B1 (ru) 2020-09-08
CL2015000352A1 (es) 2015-11-13
EA202193044A2 (ru) 2022-03-31
MX2015001601A (es) 2015-09-25
PH12015500196B1 (en) 2015-04-06
IL237153A0 (en) 2015-04-30
US20140099303A1 (en) 2014-04-10
EP2885010A4 (en) 2016-06-08
IL237153B (en) 2018-05-31
CY1123515T1 (el) 2022-03-24
PT2885010T (pt) 2020-03-11
RS60080B1 (sr) 2020-05-29
CA2882034A1 (en) 2014-02-20
LT2885010T (lt) 2020-04-27
US9567395B2 (en) 2017-02-14

Similar Documents

Publication Publication Date Title
FIC20240017I1 (fi) Rotsanoliksitsumabi
NL301173I2 (nl) amivantamab
NO2021049I1 (no) Duvelisib
NO2022024I1 (no) Roxadustat
CY2022027I2 (el) Παραγωγα βενζιμιδαζολο-προλινης
NL301079I2 (nl) isatuximab
NO2019034I1 (no) lorlatinib
HUE048780T2 (hu) Tauopátia kezelésére szolgáló módszerek
SMT201700065B (it) Derivato piridonico
CO7010838A2 (es) Compuestos de imidazopirrolidinona
HUE042218T2 (hu) Exonátugrást elõsegítõ készítmények izomdisztrófia kezelésére
DK2859055T3 (da) Polymercoatings
DK2825087T3 (da) Otoscanner
EP3586971C0 (en) Centrifuge
CU24158B1 (es) Método de obtención de 1-kestosa
PT3068786T (pt) Compostos de pirazolopirimidina
CO6990736A2 (es) Pirrolidina-2-carboxamidas sustituídas
DE112012006109A5 (de) Okklusionsschienenanordnung
DK2854722T3 (da) Stomipose
DK2825157T3 (da) Aminosyrelipider
EP2862861A4 (en) PIPERIDINYLPYRAZOLOPYRIDINDERIVAT
CO7020919A2 (es) Derivados de tetrahidro-quinazolinona
HUE046544T2 (hu) Eljárások Hepatitis C kezelésére
ME02982B (me) Benzamidi
DK2804611T3 (da) Chitosanafledte forbindelser